 |
8 Diseases |  |
4 Trials |
|
4 Trials |  |
310 News |  |
| «1234 |
- ||| Livdelzi (seladelpar) / Gilead
Enrollment change, Trial primary completion date: CB8025-21629: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov) - Aug 29, 2017
P2, N=116, Recruiting, Sponsor: CymaBay Therapeutics, Inc.
N=36 --> 116 | Trial primary completion date: Dec 2017 --> Jul 2019 | N=36 --> 116 | Trial primary completion date: Dec 2017 --> Jul 2019
- Livdelzi (seladelpar) / Gilead
Trial primary completion date: Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Jan 31, 2017
P2, N=41, Terminated, Sponsor: CymaBay Therapeutics, Inc.
N=36 --> 116 | Trial primary completion date: Dec 2017 --> Jul 2019 | N=36 --> 116 | Trial primary completion date: Dec 2017 --> Jul 2019 Trial primary completion date: Dec 2016 --> Jul 2016
- |||| Livdelzi (seladelpar) / Gilead
Enrollment open: CB8025-21629: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov) - Dec 8, 2016
P2, N=36, Recruiting, Sponsor: CymaBay Therapeutics, Inc.
Trial primary completion date: Dec 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- | seladelpar (MBX-8025) / CymaBay
Clinical: CB8025-21629: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov) - Nov 3, 2016
P2, N=36, Not yet recruiting, Sponsor: CymaBay Therapeutics, Inc.
- Livdelzi (seladelpar) / Gilead
Enrollment change, Trial termination: Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Jun 5, 2016
P2, N=41, Terminated, Sponsor: CymaBay Therapeutics, Inc.
Not yet recruiting --> Recruiting N=75 --> 41 | Recruiting --> Terminated; Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.
- | seladelpar (MBX-8025) / CymaBay
Trial completion, Enrollment change: Study to Evaluate the Effects of MBX-8025 in Patients With HoFH (clinicaltrials.gov) - Mar 9, 2016
P2, N=13, Completed, Sponsor: CymaBay Therapeutics, Inc.
N=75 --> 41 | Recruiting --> Terminated; Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction. Active, not recruiting --> Completed | N=10 --> 13
- seladelpar (MBX-8025) / CymaBay
Enrollment closed: Study to Evaluate the Effects of MBX-8025 in Patients With HoFH (clinicaltrials.gov) - Dec 9, 2015
P2, N=10, Active, not recruiting, Sponsor: CymaBay Therapeutics, Inc.
Active, not recruiting --> Completed | N=10 --> 13 Recruiting --> Active, not recruiting
- ||||| Livdelzi (seladelpar) / Gilead
New P2 trial: Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Nov 21, 2015
P2, N=75, Recruiting, Sponsor: CymaBay Therapeutics, Inc.
- seladelpar (MBX-8025) / CymaBay
New P2 trial: Study to Evaluate the Effects of MBX-8025 in Patients With HoFH (clinicaltrials.gov) - Jun 16, 2015
P2, N=10, Recruiting, Sponsor: CymaBay Therapeutics, Inc.